27052-11-5

Upstream product

• 3696-22-8 p-nitrophenylthiourea 
• 105-39-5 chloroacetic acid ethyl ester 
• 333-20-0 potassium thioacyanate 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 20949-66-0 2-methylsulfanyl-thiazol-4-one 
• 100-01-6 4-nitro-aniline 
• 79-11-8 chloroacetic acid 
• 1147550-11-5 ammonium thiocyanate 

Downstream Products

• 34765-49-6 2-(4-nitrophenylimino)-5-benzylidene-4-thiazolidinone 
• 1332862-79-9 2-(4-nitrophenylimino)-5-(2-chlorobenzylidene)-4-thiazolidinone 
• 1332862-80-2 2-(4-nitrophenylimino)-5-(4-chlorobenzylidene)-4-thiazolidinone 
• 857239-64-6 2-(4-nitrophenylimino)-5-(2-nitrobenzylidene)-4-thiazolidinone 
• 34765-48-5 2-(4-nitrophenylimino)-5-(3-nitrobenzylidene)-4-thiazolidinone 
• 101601-64-3 2-(4-nitrophenylimino)-5-(4-hydroxy-3-methoxybenzylidene)-4-thiazolidinone 

Relevant academic research and scientific papers

SO2F2-Mediated N-Alkylation of Imino-Thiazolidinones

The N-alkylation of ambident and weakly nucleophilic imino-thiazolidinones has been developed via substitution with alkyl fluorosulfonates. These reactive electrophiles are obtained through the transformation of nontoxic, economic, and commercially availa

Novel benzoic thiazolidin-4-one derivatives targeting DevR/DosR dormancy regulator of Mycobacterium tuberculosis

Latent tuberculosis infection is caused by Mycobacterium tuberculosis (Mtb) persistence and poses a significant challenge to the eradication of tuberculosis. The detection of Mtb DevR/DosR dormancy regulon expression in clinical specimens has provided evi

A Library of Thiazolidin-4-one Derivatives as Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors: An Attempt To Discover Novel Antidiabetic Agents

Protein tyrosine phosphatase 1B (PTP1B) is an important target for the treatment of diabetes. A series of thiazolidin-4-one derivatives 8–22 was designed, synthesized and investigated as PTP1B inhibitors. The new molecules inhibited PTP1B with IC50 values in the micromolar range. 5-(Furan-2-ylmethylene)-2-(4-nitrophenylimino)thiazolidin-4-one (17) exhibited potency with a competitive type of enzyme inhibition. structure–activity relationship studies revealed various structural facets important for the potency of these analogues. The findings revealed a requirement for a nitro group-including hydrophobic heteroaryl ring for PTP1B inhibition. Molecular docking studies afforded good correlation with experimental results. H-bonding and π–π interactions were responsible for optimal binding and effective stabilization of virtual protein-ligand complexes. Furthermore, in-silico pharmacokinetic properties of test compounds predicted their drug-like characteristics for potential oral use as antidiabetic agents.Additionally, a binding site model demonstrating crucial pharmacophoric characteristics influencing potency and binding affinity of inhibitors has been proposed, which can be employed in the design of future potential PTP1B inhibitors.

Novel 2-(substituted phenyl Imino)-5-benzylidene-4-thiazolidinones as possible non-ulcerogenic tri-action drug candidates: synthesis, characterization, biological evaluation And docking studies

The present research was aimed at the synthesis and screening of 35 novel 2-(substituted phenyl imino)-5-benzylidene-4-thiazolidinones having different substitutions at imino phenyl and arylidene groups. The title compounds were synthesized by Knoevenagel

Design, synthesis and molecular docking studies of some thiazole clubbed heterocyclic compounds as possible anti-infective agents

The present work describes synthesis of a series of 5-((1-(4-(4-chlorophenyl)thiazol-2-yl)-3- aryl-1H-pyrazol-4-yl)methylene)-2-(arylimino)thiazolidin-4-one derivatives and their molecular docking and biological evaluation as possible antimalarial, anthelmintic and antimicrobial agents. The synthesis of compounds has been accomplished by adopting suitable synthetic methods. Structures of newly synthesized compounds were characterized and authenticated by spectral methods such as IR, 1H-NMR and mass spectra. Synthesized compounds were screened for their in vitro antimicrobial activity against selected bacterial strains and fungal strains viz. B. subtilis, S. aureus, E. coli, P. fluorescens, C. albicans, C. glabrata and antimalarial studies against P. falciparum. Titled compounds were also tested against Pheretima posthuma (earthworm) for their anthelmintic activity. Molecular docking was done to study the binding modes of the potent compounds against Escherichia coli (PDB ID: 1AB4) and Candida P450DM (PDB ID: 1EA1) enzymes. The results revealed that all the compounds exhibited moderate to significant antimicrobial activities. Antimalarial activity screening revealed that one compound 8i showed significant antimalarial activity with of IC50; 0.59 μg/mL as compared to standard drugs chloroquine (IC50= 0.020 μg/mL) and quinine (IC50; 0.268 μg/mL). The most active compound exhibited the mean paralysis time of 19.2 ± 0.9 min and mean death time of 31.7 ± 2.5 min. It can be concluded that some of the synthesized compounds have remarkable antiinfective, antimalarial and anthelmintic activity and are suitable candidates for further scientific exploration.

Syntheses and evaluation of 2,5-disubstituted 4-thiazolidinone analogues as antimicrobial agents

Two novel series of 4-thiazolidinone derivatives, bearing 2-nitrophenyl imino and 4-nitrophenyl imino groups at position-2 and substituted arylidene groups at position-5, have been synthesized and evaluated for antimicrobial activity against four bacteria

Synthesis and biological evaluation of 7-N-(n-alkoxyphthalimido)-2hydroxy- 4-aryl-6-aryliminothiazolidino [2,3-b] pyrimidines and related compounds

Substituted aryl thioureas 1a-c react with chloroacetic acid in the presence of anhydrous sodium acetate to furnish 2-aryliminothiazolidin-4-ones 2a-c. Condensation of ω-bromoalkoxyphthalimides 3a-c with 2a-c give the corresponding alkoxyphthalimide derivatives of 2-aryliminothiazolidin-4-ones 4a-i. These on condensation with araldehydes 5a-c yield 3-N-(alkoxyphthalimido)- 5-arylidene-2-aryliminothiazolidin-4-ones 7a-a′. In an alternative route 5a-c react with 2a-c to give 6a-i, which could be cyclised with urea in the presence of sodium acetate to yield the corresponding thiazolidinopyrimidine 8a-i. 7a-a′ are also prepared from 6a-i with 3a-c, which give final compound 9a-a′ on cyclisation. Alternatively, 8a-i when condensed with 3a-c also furnish the compounds 9a-a′. Evaluation of antimalarial and antibacterial activity is also reported.